Bulletin
Investor Alert

Revolution Medicines Inc.

NAS: RVMD

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Revolution Medicines Inc.

After Hours

 --Quotes are delayed by 20 min

Mar 21, 2023, 5:23 p.m.

RVMD
/zigman2/quotes/216320743/composite

$

21.00

Change

-0.37 -1.73%

Volume

Volume 16,414

Quotes are delayed by 20 min

/zigman2/quotes/216320743/composite

Today's close

$ 21.77

$ 21.37

Change

-0.40 -1.84%

Day low

Day high

$21.32

$22.41

Open

52 week low

52 week high

$14.08

$31.37

Open

Company Description

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinica...

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Valuation

Price to Sales Ratio

54.28

Price to Book Ratio

3.14

Enterprise Value to EBITDA

-6.74

Enterprise Value to Sales

47.36

Efficiency

Total Asset Turnover

0.04

Liquidity

Current Ratio

10.65

Quick Ratio

10.65

Cash Ratio

10.41

Profitability

Gross Margin

72.71

Operating Margin

-730.01

Pretax Margin

-704.14

Net Margin

-702.95

Return on Assets

-31.01

Return on Equity

-38.63

Return on Total Capital

-36.41

Capital Structure

Total Debt to Total Assets

7.66

Officers and Executives

Name Age Officer Since Title
Dr. Mark A. Goldsmith 59 2014 Chairman, President & Chief Executive Officer
Dr. Margaret A. Horn 59 - Chief Operating Officer & General Counsel
Mr. Jack Anders 42 2018 Principal Accounting Officer & VP-Finance
Dr. Stephen M. Kelsey 61 2017 President-Research & Development
Dr. Walter Reiher - 2015 Chief Information Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
02/22/2023 Mark A. Goldsmith
See Remarks; Director 		45,000   Derivative/Non-derivative trans. at $0.49 per share. 22,050
12/19/2022 Stephen M. Kelsey
See Remarks 		1,220   Disposition at $22.94 per share. 27,986
12/19/2022 Margaret A. Horn
See Remarks 		1,220   Disposition at $22.94 per share. 27,986
12/19/2022 Xiaolin Wang
See Remarks 		708   Disposition at $22.94 per share. 16,241
12/19/2022 Jack Anders
Chief Financial Officer 		658   Disposition at $22.94 per share. 15,094
11/07/2022 Margaret A. Horn
See Remarks 		17,767   Disposition at $20.15 per share. 358,005
10/31/2022 Margaret A. Horn
See Remarks 		17,767   Disposition at $20.41 per share. 362,624
10/26/2022 Margaret A. Horn
See Remarks 		17,768   Disposition at $20.15 per share. 358,025
09/19/2022 Stephen M. Kelsey
See Remarks 		1,267   Disposition at $19.04 per share. 24,123
09/19/2022 Margaret A. Horn
See Remarks 		1,267   Disposition at $19.04 per share. 24,123
09/19/2022 Xiaolin Wang
See Remarks 		735   Disposition at $19.04 per share. 13,994
09/19/2022 Jack Anders
Chief Financial Officer 		449   Disposition at $19.04 per share. 8,548
09/01/2022 Jack Anders
Chief Financial Officer 		10,000   Award at $0 per share. 0
08/11/2022 Mark A. Goldsmith
See Remarks; Director 		10,000   Derivative/Non-derivative trans. at $0.49 per share. 4,900
08/09/2022 Mark A. Goldsmith
See Remarks; Director 		10,336   Derivative/Non-derivative trans. at $0.49 per share. 5,064
07/22/2022 Nextech Invest AG
Director 		250,000   Acquisition at $20 per share. 5,000,000
07/22/2022 Lorence H. Kim
Director 		50,000   Acquisition at $20 per share. 1,000,000
/news/latest/company/us/rvmd

MarketWatch News on RVMD

  1. Revolution Medicines upgraded to overweight from neutral at J.P. Morgan

    8:27 a.m. Feb. 28, 2023

    - Tomi Kilgore

  2. Revolution Medicines started at outperform with $30 stock price target at Oppenheimer

    7:28 a.m. Oct. 21, 2022

    - Tomi Kilgore

  3. Revolution Medicines started at neutral with $24 stock price target at BofA Securities

    10:24 a.m. May 20, 2022

    - Tomi Kilgore

  4. Revolution Medicines started at hold with $34 stock price target at Stifel Nicolaus

    7:43 a.m. Sept. 23, 2021

    - Tomi Kilgore

  5. Cancer Meeting Could Ignite These Biotech Stocks

    6:00 a.m. Oct. 24, 2020

    - Barron's Online

  6. The Pandemic Speeds Up the Health-Care Revolution

    6:01 p.m. Oct. 6, 2020

    - Barron's Online

  7. Cancer Meeting’s High Hopes for Amgen and Gilead

    8:22 a.m. Sept. 21, 2020

    - Barron's Online

  8. Why Blackstone Stock Looks Attractive

    10:29 p.m. May 22, 2020

    - Barron's Online

  11. Revolution Medicines shares soar 85% in trading debut

    12:16 p.m. Feb. 13, 2020

    - Ciara Linnane

  12. Revolution Medicines prices IPO at $17 a share

    8:56 p.m. Feb. 12, 2020

    - Jeremy C. Owens

  14. Revolution Medicines increases size of planned IPO and raises price range

    8:07 a.m. Feb. 11, 2020

    - Ciara Linnane

  15. Revolution Medicines to offer 14 mln shares in planned IPO, priced at $16 to $17 each

    8:07 a.m. Feb. 11, 2020

    - Ciara Linnane

/news/nonmarketwatch/company/us/rvmd

Other News on RVMD

  1. 10-K: REVOLUTION MEDICINES, INC.

    5:11 p.m. Feb. 27, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  2. Mass General Brigham, Inc Buys 2, Sells 3 in 4th Quarter

    1:00 p.m. Jan. 19, 2023

    - GuruFocus.com

  6. 10-Q: REVOLUTION MEDICINES, INC.

    5:13 p.m. Nov. 7, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  8. Revolution Medicines promotes Jack Anders to CFO

    8:43 a.m. Sept. 2, 2022

    - Seeking Alpha

  10. Top 5 2nd Quarter Trades of EcoR1 Capital, LLC

    7:00 p.m. Aug. 15, 2022

    - GuruFocus.com

  11. TRV GP IV, LLC Buys 3, Sells 2 in 2nd Quarter

    7:00 a.m. Aug. 15, 2022

    - GuruFocus.com

  16. 10-Q: REVOLUTION MEDICINES, INC.

    4:24 p.m. Aug. 9, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  18. Revolution Medicines prices upsized $230M equity offering

    12:21 a.m. July 20, 2022

    - Seeking Alpha

  19. Revolution Medicines to raise up to $200M in stock offering

    4:11 p.m. July 19, 2022

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Revolution Medicines, Inc.

700 Saginaw Drive

Redwood City, California 94063

Phone

1 6504816801

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2023

View SEC Filings

Revenue

$35.38M

Net Income

$-248.71M

Employees

246.00

Annual Report for RVMD

/news/pressrelease/company/us/rvmd

Press Releases on RVMD

  1. Monday 3/13 Insider Buying Report: RVMD, WTRG

    10:49 a.m. March 13, 2023

    - MarketNewsVideo.com

  21. Loading more headlines...
Link to MarketWatch's Slice.